Unlocking the future of epigenetics, with Carlos Buesa

Oncology

What if the key to treating cancer and neurodevelopmental disorders lies in how our genes are expressed, not just in the genes themselves?

In this exclusive video interview, pharmaphorum’s editor-in-chief Jonah Comstock sits down with Carlos Buesa, CEO of Oryzon Genomics, to explore how epigenetics is reshaping the landscape of oncology and CNS therapies.

Oryzon Genomics is at the forefront of epigenetic research, pioneering innovative approaches that go beyond traditional genetic treatments. Watch the video to discover how epigenetic mechanisms regulate gene expression and why they matter for personalised medicine, and learn about Oryzon’s groundbreaking clinical data in acute myeloid leukaemia, including 100% response rates and unprecedented complete remissions.

Epigenetics isn’t just a buzzword; it’s a transformational tool that could redefine treatment paradigms in oncology and neuroscience. If you’re a senior pharma leader looking to stay ahead of the curve, this conversation is a must-watch.

Watch the full interview now and see how Oryzon Genomics is shaping the future of precision medicine.

Jonah Comstock

14 January, 2026

epigenetics

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.